Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines -February 27, 2024 at 05:56 pm EST

Veracyte, Inc. , a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in...

Related Keywords

Elai Davicioni ,Nasdaq ,Twitter ,National Comprehensive Cancer Network ,Veracyte Inc ,Decipher Prostate Genomic Classifier ,Clinical Practice Guidelines ,Decipher Prostate ,Decipher Prostate Genomic ,Veracyte Diagnostics Platform ,Annual Report ,Quarterly Report ,National Comprehensive Cancer ,Markets ,